Literature DB >> 15470202

Natural infection of infants with respiratory syncytial virus subgroups A and B: a study of frequency, disease severity, and viral load.

John P Devincenzo1.   

Abstract

Heterogeneity in respiratory syncytial virus (RSV) disease severity likely is due to a combination of host and viral factors. Infection with RSV subgroup A is thought to produce more severe disease than RSV-B. Higher RSV loads correlate with greater disease severity in hospitalized infants. Whether subgroup-specific variations in disease severity result from differences in RSV load has not been studied. A total of 102 RSV-hospitalized infants <2 y of age were studied. Nasal washes were collected in a standardized manner and were cultured in <3 h in parallel with an RSV quantitative standard in a HEp-2 plaque assay. RSV-A (72%) was more frequent than RSV-B. Disease severity risk factors were similar between subgroups. RSV loads were similar between A and B subgroups (4.77 versus 4.68 log PFU/mL). Measures of disease severity were also similar between subgroups.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15470202     DOI: 10.1203/01.PDR.0000145255.86117.6A

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  35 in total

1.  Evaluation of IgG Antibodies Against Respiratory Syncytial Virus (RSV), and Associated Risk Factors for Severe Respiratory Tract Infections in Pre-School Children in North-Central, Nigeria.

Authors:  Adedayo Faneye; Babatunde O Motayo; Adeyinka Adesanmi; Bernard Onoja
Journal:  Afr J Infect Dis       Date:  2014

2.  Analysis of host genetic diversity and viral entry as sources of between-host variation in viral load.

Authors:  Andrew R Wargo; Alison M Kell; Robert J Scott; Gary H Thorgaard; Gael Kurath
Journal:  Virus Res       Date:  2012-01-30       Impact factor: 3.303

3.  Respiratory syncytial virus load, viral dynamics, and disease severity in previously healthy naturally infected children.

Authors:  Chadi M El Saleeby; Andy J Bush; Lisa M Harrison; Jody A Aitken; John P Devincenzo
Journal:  J Infect Dis       Date:  2011-10-01       Impact factor: 5.226

4.  Viral load drives disease in humans experimentally infected with respiratory syncytial virus.

Authors:  John P DeVincenzo; Tom Wilkinson; Akshay Vaishnaw; Jeff Cehelsky; Rachel Meyers; Saraswathy Nochur; Lisa Harrison; Patricia Meeking; Alex Mann; Elizabeth Moane; John Oxford; Rajat Pareek; Ryves Moore; Ed Walsh; Robert Studholme; Preston Dorsett; Rene Alvarez; Robert Lambkin-Williams
Journal:  Am J Respir Crit Care Med       Date:  2010-07-09       Impact factor: 21.405

5.  A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus.

Authors:  John DeVincenzo; Robert Lambkin-Williams; Tom Wilkinson; Jeffrey Cehelsky; Sara Nochur; Edward Walsh; Rachel Meyers; Jared Gollob; Akshay Vaishnaw
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-26       Impact factor: 11.205

6.  Identification of residues in the human respiratory syncytial virus fusion protein that modulate fusion activity and pathogenesis.

Authors:  Anne L Hotard; Sujin Lee; Michael G Currier; James E Crowe; Kaori Sakamoto; Dawn C Newcomb; R Stokes Peebles; Richard K Plemper; Martin L Moore
Journal:  J Virol       Date:  2014-10-22       Impact factor: 5.103

7.  Reverse genetics systems for contemporary isolates of respiratory syncytial virus enable rapid evaluation of antibody escape mutants.

Authors:  Wendy K Jo; Alina Schadenhofer; Andre Habierski; Franziska K Kaiser; Giulietta Saletti; Tina Ganzenmueller; Elias Hage; Sibylle Haid; Thomas Pietschmann; Gesine Hansen; Thomas F Schulz; Guus F Rimmelzwaan; Albert D M E Osterhaus; Martin Ludlow
Journal:  Proc Natl Acad Sci U S A       Date:  2021-04-06       Impact factor: 11.205

Review 8.  Human genetic factors and respiratory syncytial virus disease severity.

Authors:  Isao Miyairi; John P DeVincenzo
Journal:  Clin Microbiol Rev       Date:  2008-10       Impact factor: 26.132

9.  Palivizumab: a review of its use in the protection of high risk infants against respiratory syncytial virus (RSV).

Authors:  Joseph M Geskey; Neal J Thomas; Gretchen L Brummel
Journal:  Biologics       Date:  2007-03

10.  Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants.

Authors:  Asunción Mejías; Octavio Ramilo
Journal:  Biologics       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.